<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39445010</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series.</ArticleTitle><Pagination><StartPage>1441620</StartPage><MedlinePgn>1441620</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1441620</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1441620</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Inflammatory factors released during severe coronavirus disease-19 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are known to influence drug exposure, but data on the effect of mild infection are few. Here we describe for the first time an increase in plasma imatinib and norimatinib concentrations observed in a series of 5 patients treated with imatinib for gastrointestinal stromal tumor (GIST) after mild COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The patients were undergoing routine therapeutic drug monitoring (TDM) and pharmacogenetic (PGx) analyses of polymorphisms in genes involved in imatinib metabolism and transport (<i>CYP3A4</i>, <i>CYP3A5</i>, <i>ABCB1</i>, and <i>ABCG2</i>) when SARS-CoV-2 infection occurred. Imatinib and its active metabolite norimatinib concentrations were determined at C<sub>trough</sub> using a validated LC-MS/MS method. PGx analyses were performed by KASP genotyping assays on a Real-Time PCR system. All patients received imatinib 400 mg/day. Case 1 was prospectively monitored. Cases 2-5 were identified retrospectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">On average, imatinib C<sub>trough</sub> increased significantly by 70% during COVID-19, whereas norimatinib showed a 44% increase compared with pre-COVID-19 levels. Elevated plasma imatinib concentrations persisted up to 6 months after infection remission. In 3 cases, this increase reflected the occurrence or worsening of imatinib side effects.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This case-series highlights the clinical impact of SARS-CoV-2 infection on the management of patients with GIST treated with imatinib.</AbstractText><CopyrightInformation>Copyright © 2024 Gagno, Posocco, Orleni, Cecchin, Fumagalli, Guardascione, Buonadonna, Polesel, Puglisi, Toffoli and Cecchin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gagno</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posocco</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orleni</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecchin</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guardascione</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buonadonna</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polesel</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puglisi</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, UD, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toffoli</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecchin</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="Y">Imatinib Mesylate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046152" MajorTopicYN="Y">Gastrointestinal Stromal Tumors</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005770" MajorTopicYN="N">Gastrointestinal Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">TDM</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">imatinib</Keyword><Keyword MajorTopicYN="N">pharmacogenetics</Keyword></KeywordList><CoiStatement>Author FP has received honoraria from Amgen - Astrazeneca - Daiichi Sankyo - Celgene - Eisai - Eli Lilly- - Exact Sciences- Gilead - Ipsen - Italfarmaco - Menarini- MSD - Novartis - Pierre Fabre - Pfizer - Roche - Seagen - Takeda - Viatris. Author FP is currently receiving research funding from Astrazeneca, EISAI, Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39445010</ArticleId><ArticleId IdType="pmc">PMC11497461</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1441620</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang G, Xiao B, Deng J, Gong L, Li Y, Li J, et al. . The role of cytochrome P450 enzymes in COVID-19 pathogenesis and therapy. Front Pharmacol. (2022) 13:791922. doi: 10.3389/fphar.2022.791922/full</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.791922/full</ArticleId><ArticleId IdType="pmc">PMC8847594</ArticleId><ArticleId IdType="pubmed">35185562</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Ghiaty MA, Shoieb SM, El-Kadi AOS. Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms. Med Hypotheses. (2020) 144:110033. doi: 10.1016/j.mehy.2020.110033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110033</ArticleId><ArticleId IdType="pmc">PMC7318945</ArticleId><ArticleId IdType="pubmed">32758877</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb S, Arrighi S. Potential effects of COVID-19 on cytochrome P450-mediated drug metabolism and disposition in infected patients. Eur J Drug Metab Pharmacokinet. (2021) 46:185–203. doi: 10.1007/s13318-020-00668-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13318-020-00668-8</ArticleId><ArticleId IdType="pmc">PMC7859725</ArticleId><ArticleId IdType="pubmed">33538960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, et al. . Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos. (2005) 33:1503–12. doi: 10.1124/dmd.105.004283</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.105.004283</ArticleId><ArticleId IdType="pubmed">16006570</ArticleId></ArticleIdList></Reference><Reference><Citation>Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JHM. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs. (2009) 27:31–40. doi: 10.1007/s10637-008-9138-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-008-9138-z</ArticleId><ArticleId IdType="pubmed">18449471</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke WA, Chatelut E, Fotoohi AK, Larson RA, Martin JH, Mathijssen RHJ, et al. . Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. (2021) 157:428–40. doi: 10.1016/j.ejca.2021.08.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2021.08.033</ArticleId><ArticleId IdType="pubmed">34597977</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalle Fratte C, Gagno S, Roncato R, Polesel J, Zanchetta M, Buzzo M, et al. . CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients. Br J Clin Pharmacol. (2022) 30:1089–98. doi: 10.1111/bcp.15551</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15551</ArticleId><ArticleId IdType="pubmed">36178950</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagno S, Buonadonna A, Dalle Fratte C, Guardascione M, Zanchetta M, Posocco B, et al. . The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure. Daru. (2023) 31:267–72. doi: 10.1007/s40199-023-00465-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40199-023-00465-z</ArticleId><ArticleId IdType="pmc">PMC10624793</ArticleId><ArticleId IdType="pubmed">37318715</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalle Fratte C, Polesel J, Gagno S, Posocco B, De Mattia E, Roncato R, et al. . Impact of ABCG2 and ABCB1 polymorphisms on imatinib plasmatic exposure: an original work and meta-analysis. Int J Mol Sci. (2023) 24:3303. doi: 10.3390/ijms24043303</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24043303</ArticleId><ArticleId IdType="pmc">PMC9963452</ArticleId><ArticleId IdType="pubmed">36834713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartelink IH, Bet PM, Widmer N, Guidi M, Duijvelaar E, Grob B, et al. . Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study. CPT Pharmacometrics Syst Pharmacol. (2021) 10:1497–511. doi: 10.1002/psp4.v10.12</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.v10.12</ArticleId><ArticleId IdType="pmc">PMC8646516</ArticleId><ArticleId IdType="pubmed">34608769</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama NN, Yang Z, o. t. BT, Ho RJY. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci. (2006) 95:2293–308. doi: 10.1002/jps.20717</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.20717</ArticleId><ArticleId IdType="pubmed">16883550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenoir C, Terrier J, Gloor Y, Curtin F, Rollason V, Desmeules JA, et al. . Impact of SARS-coV-2 infection (COVID-19) on cytochromes P450 activity assessed by the geneva cocktail. Clin Pharmacol Ther. (2021) 110:1358–67. doi: 10.1002/cpt.v110.5</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.v110.5</ArticleId><ArticleId IdType="pmc">PMC8653122</ArticleId><ArticleId IdType="pubmed">34473836</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemure S, Trenaman SC, Goralski KB. The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions. Expert Opin Drug Metab Toxicol. (2023) 19:329–32. doi: 10.1080/17425255.2023.2228680</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425255.2023.2228680</ArticleId><ArticleId IdType="pubmed">37345482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. (2020) 108:17–41. doi: 10.1002/JLB.3COVR0520-272R</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3COVR0520-272R</ArticleId><ArticleId IdType="pmc">PMC7323250</ArticleId><ArticleId IdType="pubmed">32534467</ArticleId></ArticleIdList></Reference><Reference><Citation>van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, et al. . Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res. (2007) 13:7394–400. doi: 10.1158/1078-0432.CCR-07-0346</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-07-0346</ArticleId><ArticleId IdType="pubmed">18094422</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawant-Basak A, Olabode D, Dai D, Vishwanathan K, Phipps A. Assessing trends in cytokine-CYP drug interaction and relevance to drug dosing. Drug Metab Dispos. (2024). doi: 10.1124/dmd.123.001499</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.123.001499</ArticleId><ArticleId IdType="pubmed">38383116</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. (2022) 23:210–6. doi: 10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Aman J, Duijvelaar E, Botros L, Kianzad A, Schippers JR, Smeele PJ, et al. . Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. (2021) 9:957–68. doi: 10.1016/S2213-2600(21)00237-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00237-X</ArticleId><ArticleId IdType="pmc">PMC8232929</ArticleId><ArticleId IdType="pubmed">34147142</ArticleId></ArticleIdList></Reference><Reference><Citation>Bins S, Eechoute K, Kloth JSL, de Man FM, Oosten AW, de Bruijn P, et al. . Prospective analysis in GIST patients on the role of alpha-1 acid glycoprotein in imatinib exposure. Clin Pharmacokinet. (2017) 56:305–10. doi: 10.1007/s40262-016-0441-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-016-0441-0</ArticleId><ArticleId IdType="pmc">PMC5315737</ArticleId><ArticleId IdType="pubmed">27461250</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Guo T, Ma Z, Du L, Hou J, Tian Y, et al. . Correlation between N-demethyl imatinib trough concentration and serious adverse reactions in patients with gastrointestinal stromal tumors: A retrospective cohort study. Ther Drug Monitoring. (2024) 46:344. doi: 10.1097/FTD.0000000000001160</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FTD.0000000000001160</ArticleId><ArticleId IdType="pubmed">38176855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagno S, Fratte CD, Posocco B, Buonadonna A, Fumagalli A, Guardascione M, et al. . Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation. Pharmacogenomics. (2023) 24:895–900. doi: 10.2217/pgs-2023-0198</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pgs-2023-0198</ArticleId><ArticleId IdType="pubmed">37955064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed MR, Mohile SG, Juba KM, Awad H, Wells M, Loh KP, et al. . Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer. (2023) 129:1096–104. doi: 10.1002/cncr.v129.7</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.v129.7</ArticleId><ArticleId IdType="pmc">PMC10958985</ArticleId><ArticleId IdType="pubmed">36692475</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>